TP53 and ureter neoplasm: Correspondingly, significantly more GAs in TP53 (70.18% vs. 40.54%) and Cell Cycle (22.81% vs. 9.46%) signaling pathways were observed within patients with ureter tumors, compared with those with renal pelvis tumors (Figure 5C).